Home > Formulary : Adult > Recent Decisions > 2013 >
Decisions 26th February 2013
Recent JFG Decisions
At the meeting on the 26th February 2013 following actions / changes to the formulary were agreed:
New Drug Requests
Approved
Methylnaltrexone
- Approved for use on the advice of palliative care team - TLS Blue
MagTab®
- Approved for use by Renal Consultant only - TLS Red
Urocit K®
- Approved for use by Renal Consultant only in patients for the treatment of distal renal tubular acidosis and hypocitraturia second line to Potassium Citrate BP Liquid - TLS Red
Doublebase Dayleve® Gel
- Recommended to be added to formulary TLS Green
Ranolazine (NBT)
- Recommended to be added to formulary in line with UHB TLS Red
Recommended but awaiting funding agreement - to be added once received
Alteplase and Dornase Alfa
- Recommended to be added to the formulary NBT Pleural Services only TLS Red - awaiting funding agreement
Not Approved
Dapagliflozin
- Not approved - await NICE TA publication
Botox for the treatment of Raynaud’s disease of the hand
- Not approved
Suboxone
- Not approved
Aflibercept (sequential use after Lucentis® failure)
- Not approved
Specialised Commissioning
Ivacaftor
- Specialised Commissioning policy - to be added to formulary TLS Red
Hizentra® Subcutaneous IVIg NBT
- Recommended to be added as already on formulary for UHB TLS Red
Fingolimod for relapsing remitting MS (not meeting NICE 254 criteria)
- Not approved as this service is commissioned by Specialised Commissioning from 1st April 2013
Cancer Drugs Fund
Ruxolitinib
- Individual patient request to be forwarded to the cancer drugs fund - not to be added to formulary. Will be considered for inclusion to formulary once NICE TA published